David Gottlieb is the Managing Partner of Noble Bridge Group LLC, a financial consulting company he established in early 2004. Also since 2004, Mr. Gottlieb has served as a Director of ABIOMED, a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. From 1990 to 2003, Mr. Gottlieb held various investment banking positions most recently as Global Head of the Medical Technology Corporate and Investment Banking Group of Banc of America Securities. In this role, he was responsible for the sector team covering nearly 300 companies globally in the medical device and hospital supply industry as well as the life science tools, in-vitro diagnostics and diagnostic imaging industries.
Previously, he held a number of positions overseeing investment banking for life science companies, including at UBS Investment Bank and Kidder, Peabody & Co. Incorporated. Mr. Gottlieb has completed more than $45 billion in corporate banking, investment banking and strategic advisory transactions such as mergers and acquisitions in the medical technology, biotechnology and health care services fields.
David Gottlieb's degrees include a Bachelor's degree in Economics from Connecticut College and a Master's in Business Administration from the Columbia Business School.
I would say you know, again, depending on what you've got, don't think an initial public offering needs to be - needs to be 10 years in the future. I took a company public back in 1998. A company called Cardiothoracic Systems, they develop surgical devices for minimal evasive coronary artery bypas...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login
David Sinclair Shares Thoughts on Time Requirements of Being a Scientist and Entrepreneur
David Gottlieb Discusses Importance of Reducing Risk In Transitioning Technology To A Commercial Enterprise
David Gottlieb States Initial Public Offering May Not Be Too Far Off As A Financing Option
